مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

319
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

221
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

ANTIBODY AGAINST INTERFERON-α 2B SERUM OF THE PATIENTS WITH CHRONIC HEPATITIS C AND ITS CLINICAL SIGNI-FICANCE: A CLINICAL

Pages

  103-109

Abstract

 Background and Aims: HEPATITIS C virus (HCV) infection is treated with alpha interferon (IFN-a). The mechanisms by which IFN-a suppresses HCV replication are not well-known; only limited benefits are achieved with the therapy because the virus in turn, directs some mechanisms to resist the host IFN-a response. The present study was undertaken to determine the therapeutic effects of IFN-a 2b and to measure the serum level of antibody against IFN-a 2b (anti-IFN-α 2b) after TREATMENT with IFN-a 2b in patients with chronic HEPATITIS C. Methods: The levels of HCV antibody (anti-HCV), HCV-RNA and anti-IFN-a 2b immunoglobulin G (IgG) in serum of 94 patients with chronic HEPATITIS C who were treated with IFN-a 2b (three 3-MU injections per week for 3 months), were measured in different courses of TREATMENT.Results: The total negative rates for anti-HCV and HCV-RNA were 33% (31/94) and 38% (36/94) in patients treated with IFN-a 2b, respectively. The rates for those treated with routine medications were 10% (4/40), 15% (6/40), respectively (P<0.01). After the first, second and third course of TREATMENT with IFN-a 2b, the negative rates of anti- HCV, HCV-RNA in serum were 0% (0/94), 15% (14/94) and 21% (20/94), 23% (22/94) and 33% (31/94), 38% (36/94), respectively. After the TREATMENT with IFN-a 2b, the total positive rate of anti-IFN-a 2b IgG was 5% (5/94). There was no significant difference between the two TREATMENT groups (P>0.05). Among them, after TREATMENT with IFN-a 2b for three, six and 12 months, the positive rates of anti-IFN-a 2b IgG were 0% (0/94), 2% (2/94), 5% (5/94), respectively. The productive ability of anti-IFN-a 2b IgG was similar during the different courses of TREATMENT with IFN-a 2b (P>0.05). Conclusions: IFN-a 2b has curative effect for patients with chronic HEPATITIS C and its therapeutic efficacy is better than that of routine TREATMENTs. Although IFN-a 2b has certain antigenicity, anti-IFN-a 2b IgG production is seen in only a few of patients during the course of TREATMENT; the restrain effect of anti-IFN-α 2b IgG on the further TREATMENT with IFN-a 2b is weak.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    JIAN, W., PINGPING, W., & GUIJU, X.. (2009). ANTIBODY AGAINST INTERFERON-α 2B SERUM OF THE PATIENTS WITH CHRONIC HEPATITIS C AND ITS CLINICAL SIGNI-FICANCE: A CLINICAL. HEPATITIS MONTHLY, 9(2 (23)), 103-109. SID. https://sid.ir/paper/306227/en

    Vancouver: Copy

    JIAN W., PINGPING W., GUIJU X.. ANTIBODY AGAINST INTERFERON-α 2B SERUM OF THE PATIENTS WITH CHRONIC HEPATITIS C AND ITS CLINICAL SIGNI-FICANCE: A CLINICAL. HEPATITIS MONTHLY[Internet]. 2009;9(2 (23)):103-109. Available from: https://sid.ir/paper/306227/en

    IEEE: Copy

    W. JIAN, W. PINGPING, and X. GUIJU, “ANTIBODY AGAINST INTERFERON-α 2B SERUM OF THE PATIENTS WITH CHRONIC HEPATITIS C AND ITS CLINICAL SIGNI-FICANCE: A CLINICAL,” HEPATITIS MONTHLY, vol. 9, no. 2 (23), pp. 103–109, 2009, [Online]. Available: https://sid.ir/paper/306227/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button